[The effectiveness of the new morantel sustained-release trilaminate bolus against gastrointestinal nematode infections in cattle in their first grazing period].
The efficacy of a recently developed Morantel-Sustained-Release-Trilaminate-Bolus (Paratect Flex Bolus [PFB]-Pfizer Inc.) against gastrointestinal nematode infections in cattle was assessed by monitoring faecal egg counts (EpG), herbage larval counts, serum pepsinogen levels and liveweight gains in first season calves. In two field trials (1987 and 1988), a PFB-Bolus was administered to two different groups of animals (1987: 15 calves; 1988:13 calves) at turnout (29 May 1987; 26 May 1988), control groups were included. In 1988, 13 calves received for comparison an Oxfendazole-Release-Bolus (Systamex Intervall Bolus [OXF]-Coopers Inc.). All groups were grazed on adjacent but separately fenced pastures throughout the season, until housing (27 October 1987; 15 October 1988). When compared with controls, the PFB-groups showed significantly lower EpG values and consequently, lower herbage larval counts throughout the season in both trials. From day 30 after turnout, the PFB-group had significantly lower serum pepsinogen levels, which reflects the low degree of abomasal damage in these animals. When compared to controls, the PFB-treated animals showed significantly higher weight performances. The mean weight-gain benefit of PFB-treated animals was +12.5 kg (p less than 0.05) and +21.1 kg (p less than 0.005) in 1987 and 1988, resp. No difference occurred between PFB-treated and OXF-treated calves, the latter outperformed the control animals by +21.6 kg (p less than 0.005).